skip to main content
Idioma:

Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real‐life study

Patruno, C. ; Napolitano, M. ; Argenziano, G. ; Peris, K. ; Ortoncelli, M. ; Girolomoni, G. ; Offidani, A. ; Ferrucci, S.M. ; Amoruso, G.F. ; Rossi, M. ; Stingeni, L. ; Malara, G. ; Grieco, T. ; Foti, C. ; Gattoni, M. ; Loi, C. ; Iannone, M. ; Talamonti, M. ; Stinco, G. ; Rongioletti, F. ; Pigatto, P.D. ; Cristaudo, A. ; Nettis, E. ; Corazza, M. ; Guarneri, F. ; Amerio, P. ; Esposito, M. ; Belloni Fortina, A. ; Potenza, C. ; Fabbrocini, G. ; Angileri, L. ; Bianchelli, T. ; Borghi, A. ; Buligan, C. ; Calabrese, G. ; Calzavara Pinton, P. ; Caroppo, F. ; Chello, C. ; Dal Bello, G. ; Damiani, G. ; Fargnoli, M.C. ; Ferrillo, M. ; Galluzzo, M. ; Gori, N. ; Gualdi, G. ; Hansel, K. ; Macchia, L. ; Mariano, M. ; Nisticò, S.P. ; Pertusi, G. ; Piras, V. ; Provenzano, E. ; Ravaioli, G.M. ; Ribero, S. ; Romanelli, M. ; Romita, P. ; Tolino, E. ; Trifirò, C.

Journal of the European Academy of Dermatology and Venereology, 2021-04, Vol.35 (4), p.958-964 [Periódico revisado por pares]

England

Texto completo disponível

Citações Citado por
  • Título:
    Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real‐life study
  • Autor: Patruno, C. ; Napolitano, M. ; Argenziano, G. ; Peris, K. ; Ortoncelli, M. ; Girolomoni, G. ; Offidani, A. ; Ferrucci, S.M. ; Amoruso, G.F. ; Rossi, M. ; Stingeni, L. ; Malara, G. ; Grieco, T. ; Foti, C. ; Gattoni, M. ; Loi, C. ; Iannone, M. ; Talamonti, M. ; Stinco, G. ; Rongioletti, F. ; Pigatto, P.D. ; Cristaudo, A. ; Nettis, E. ; Corazza, M. ; Guarneri, F. ; Amerio, P. ; Esposito, M. ; Belloni Fortina, A. ; Potenza, C. ; Fabbrocini, G. ; Angileri, L. ; Bianchelli, T. ; Borghi, A. ; Buligan, C. ; Calabrese, G. ; Calzavara Pinton, P. ; Caroppo, F. ; Chello, C. ; Dal Bello, G. ; Damiani, G. ; Fargnoli, M.C. ; Ferrillo, M. ; Galluzzo, M. ; Gori, N. ; Gualdi, G. ; Hansel, K. ; Macchia, L. ; Mariano, M. ; Nisticò, S.P. ; Pertusi, G. ; Piras, V. ; Provenzano, E. ; Ravaioli, G.M. ; Ribero, S. ; Romanelli, M. ; Romita, P. ; Tolino, E. ; Trifirò, C.
  • Assuntos: Adolescent ; Adult ; Aged ; Antibodies, Monoclonal, Humanized ; Dermatitis, Atopic - drug therapy ; Eczema ; Humans ; Middle Aged ; Retrospective Studies ; Severity of Illness Index ; Young Adult
  • É parte de: Journal of the European Academy of Dermatology and Venereology, 2021-04, Vol.35 (4), p.958-964
  • Notas: Funding sources
    Conflict of interest
    C.P. acted as speaker, consultant and advisory board member for AbbVie, Novartis, Pfizer and Sanofi. M.N. acted as speaker, consultant and advisory board member for Sanofi, Abbvie, Leo Pharma and Novartis. K.P. reports grants and personal fees from Almirall and AbbVie and personal fees from Biogen, Lilly, Celgene, Galderma, Leo Pharma, Novartis Pierre Fabre, Sanofi, Sandoz, Sun Pharma and Janssen, outside the submitted work. M.O acted as speaker for AbbVie, Novartis, Sanofi. G.G. has been principal investigator in clinical trials sponsored by and/or and has received personal fees from AbbVie, Abiogen, Almirall, Alphasights, Amgen, Biogen, Bristol‐Meyers Squibb, Celgene, Celltrion, Eli Lilly, Genzyme Gerson Lehrman Group, Guidepoint Global, Leo Pharma, Menlo Therapeutics, Novartis, OM Pharma, Pfizer, Regeneron, Samsung, Sandoz and UCB. A.O. acted as advisory board member, investigator, speaker for AbbVie, Celgene, Eli Lilly, Galderma, Janssen, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme. S.M.F. is speaker of Novartis and Sanofi Genzyme, is principal investigator for Eli Lilly, AbbVie, Sanofi Genzyme and is an advisory member of Sanofi Genzyme. L.S acted as speaker and board member for Sanofi Genzyme. C.F acted as speaker for AbbVie, Novartis, Sanofi. G.S. has been principal investigator in clinical trials sponsored and received honoraria for lectures and research grants from Novartis, AbbVie, Janssen‐Cilag, Eli Lilly, Leo Pharma, Sandoz, UCB. F.R. acted as board advisor member for Sanofi. E.N. in the past 5 years accepted a fee for organizing education for Sanofi. F.G acted as advisory board member for Sanofi. P.A. acted as speaker for Sanofi. M.E. acted as a consultant, speaker and/or board member for Eli Lilly, Novartis, Janssen, Sanofi Genzyme, UCB. C.P. acted as consultant and speaker for AbbVie, Almirall, Celgene, Leo Pharma, Novartis, Pfizer, Parexel, Sanofi, Janssen, Lilly. G.F. has been principal investigator in clinical trials sponsored by and/or and has received personal fees from AbbVie, Abiogen, Almirall, Celgene, Eli Lilly, Leo Pharma, Novartis, Sanofi, and UCB.
    see Appendix 11
    None declared.
    ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
  • Descrição: Background Treatment of moderate‐to‐severe atopic dermatitis (AD) in the elderly may be challenging, due to side‐effects of traditional anti‐inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab are not yet well known. Objectives A multicentre retrospective, observational, real‐life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥65 years and affected by severe AD. Their main clinical features were also examined. Methods Data of elderly patients with severe (EASI ≥24) AD treated with dupilumab at label dosage for 16 weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P‐NRS, S‐NRS and DLQI) scores at baseline and after 16 weeks of treatment. Results Two hundred and seventy‐six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis. The coexistence of more than one phenotype was found in 63/276 (22.82%) subjects. Data on the 16‐week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18–64 years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty‐one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event. Conclusions Therapy with dupilumab led to a significant improvement of AD over a 16‐week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe treatment for AD also in the elderly.
  • Editor: England
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.